HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · IEX Real-Time Price · USD
1.377
-0.113 (-7.58%)
At close: May 1, 2024, 3:44 PM
1.350
-0.027 (-1.96%)
After-hours: May 1, 2024, 4:00 PM EDT
HCW Biologics Revenue
In the year 2023, HCW Biologics had annual revenue of $560.36K, a decrease of -78.33%. Revenue in the quarter ending December 31, 2023 was $252.65K, a -5.84% decrease year-over-year.
Revenue (ttm)
$560.36K
Revenue Growth
-78.33%
P/S Ratio
92.93
Revenue / Employee
$12,452
Employees
45
Market Cap
52.08M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 560.36K | -2.03M | -78.33% |
Dec 31, 2022 | 2.59M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 4.10M | - | - |
Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHCWB News
- 4 weeks ago - HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights - GlobeNewsWire
- 6 months ago - HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights - GlobeNewsWire
- 6 months ago - Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting - GlobeNewsWire
- 6 months ago - Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting - GlobeNewsWire
- 8 months ago - HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023 - GlobeNewsWire
- 9 months ago - HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 11 months ago - HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders - GlobeNewsWire
- 1 year ago - HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights - GlobeNewsWire